Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

418 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to Letter to the Editor.
Boehnke T, Bauerfeind A, Eggebrecht L, Cellier C, Lange JA, Heinemann K, Madden T. Boehnke T, et al. Among authors: madden t. Contraception. 2024 May 11:110481. doi: 10.1016/j.contraception.2024.110481. Online ahead of print. Contraception. 2024. PMID: 38740277 No abstract available.
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.
Levis M, Perl A, Schiller G, Fathi AT, Roboz G, Wang ES, Altman J, Rajkhowa T, Ando M, Suzuki T, Subach RA, Maier G, Madden T, Johansen M, Cheung K, Kurman M, Smith C. Levis M, et al. Among authors: madden t. Blood Adv. 2024 May 28;8(10):2527-2535. doi: 10.1182/bloodadvances.2023010619. Blood Adv. 2024. PMID: 38502195 Free PMC article. Clinical Trial.
LETd Optimization Verification With an SOI Microdosimeter.
Pan VA, Tran LT, Madden T, Clasie B, Kooy H, Rosenfeld AB, Depauw N. Pan VA, et al. Among authors: madden t. Int J Radiat Oncol Biol Phys. 2024 Jan 31:S0360-3016(23)08310-4. doi: 10.1016/j.ijrobp.2023.12.036. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38300188
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.
Gbinigie O, Ogburn E, Allen J, Dorward J, Dobson M, Madden TA, Yu LM, Lowe DM, Rahman N, Petrou S, Richards D, Hood K, Patel M, Saville BR, Marion J, Holmes J, Png ME, Hayward G, Lown M, Harris V, Jani B, Hart N, Khoo S, Rutter H, Chalk J, Standing JF, Breuer J, Lavallee L, Hadley E, Cureton L, Benysek M, Andersson MI, Francis N, Thomas NPB, Evans P, van Hecke O, Koshkouei M, Coates M, Barrett S, Bateman C, Davies J, Raymundo-Wood I, Ustianowski A, Nguyen-Van-Tam J, Carson-Stevens A, Hobbs R, Little P, Butler CC. Gbinigie O, et al. Among authors: madden ta. BMJ Open. 2023 Aug 7;13(8):e069176. doi: 10.1136/bmjopen-2022-069176. BMJ Open. 2023. PMID: 37550022 Free PMC article.
418 results